Exact Mass: 285.0896

Exact Mass Matches: 285.0896

Found 93 metabolites which its exact mass value is equals to given mass value 285.0896, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Buchananine

ZINC00898995

C12H15NO7 (285.0848)


   

Fludarabine

Fludarabine Base

C10H12FN5O4 (285.0873)


L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BB - Purine analogues C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2150 - Ribonucleotide Reductase Inhibitor D000970 - Antineoplastic Agents Fludarabine (NSC 118218) is a DNA synthesis inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies. Fludarabine inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes[1][2][3][4].

   

N-Acetylcytidine

N(4)-acetylcytidine

C11H15N3O6 (285.0961)


Cytidine in which one of the exocyclic amino hydrogens is substituted by an acetyl group. N4-Acetylcytidine is an endogenous metabolite. N4-Acetylcytidine is an endogenous metabolite.

   

4-nitrophenyl-alpha-l-fucopyranoside

p-Nitrophenyl 6-deoxy-alpha-L-galactopyranoside

C12H15NO7 (285.0848)


   

N4-Acetylcytidine

N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}acetamide

C11H15N3O6 (285.0961)


N4-Acetylcytidine is a modified nucleoside. N4-acetylcytidine is an endogenous urinary nucleoside product of the degradation of transfer ribonucleic acid (tRNA); urinary nucleosides are biological markers for patients with colorectal cancer. tRNA has been shown to be excreted in abnormal amounts in the urine of cancer patients. tRNA from neoplastic tissue had a much more rapid turnover rate than the tRNA from the corresponding normal tissue. Evidence indicates that methylation of tRNA occurs only after synthesis of the intact macromolecule. Because there are no specific enzyme systems to incorporate the modified nucleosides into the macromolecular nucleic acid, these nucleosides once released in the process of tRNA turnover cannot be reutilized, nor are they further degraded, but are excreted in urine. (PMID: 15991285, 3506820) [HMDB] N4-Acetylcytidine is a modified nucleoside. N4-acetylcytidine is an endogenous urinary nucleoside product of the degradation of transfer ribonucleic acid (tRNA); urinary nucleosides are biological markers for patients with colorectal cancer. tRNA has been shown to be excreted in abnormal amounts in the urine of cancer patients. tRNA from neoplastic tissue had a much more rapid turnover rate than the tRNA from the corresponding normal tissue. Evidence indicates that methylation of tRNA occurs only after synthesis of the intact macromolecule. Because there are no specific enzyme systems to incorporate the modified nucleosides into the macromolecular nucleic acid, these nucleosides once released in the process of tRNA turnover cannot be reutilized, nor are they further degraded, but are excreted in urine. (PMID: 15991285, 3506820). N4-Acetylcytidine is an endogenous metabolite. N4-Acetylcytidine is an endogenous metabolite.

   

Asenapine

17-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.0^{2,6}.0^{7,12}]octadeca-1(14),7,9,11,15,17-hexaene

C17H16ClNO (285.092)


   

2-Fluoroadenosine

2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

C10H12FN5O4 (285.0873)


   

arabinosyl-2-fluoroadenine

2-(6-amino-2-fluoro-7H-purin-8-yl)oxane-3,4,5-triol

C10H12FN5O4 (285.0873)


   

4-(2-Methoxyphenyl)-2-((5-methyl-1H-imidazol-4-yl)methyl)thiazole

4-(2-methoxyphenyl)-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1,3-thiazole

C15H15N3OS (285.0936)


   

Flunoxaprofen

2-[2-(4-fluorophenyl)-1,3-benzoxazol-5-yl]propanoic acid

C16H12FNO3 (285.0801)


   
   

N-glucosylnicotinate

N-glucosylnicotinate

C12H15NO7 (285.0848)


   

aleurodiscoester

aleurodiscoester

C12H15NO7 (285.0848)


   

O1-(3-amino-phenyl)-beta-D-glucopyranuronic acid|O1-(3-Amino-phenyl)-beta-D-glucopyranuronsaeure

O1-(3-amino-phenyl)-beta-D-glucopyranuronic acid|O1-(3-Amino-phenyl)-beta-D-glucopyranuronsaeure

C12H15NO7 (285.0848)


   

4-Aminophenyl-beta-D-glucuronide

4-Aminophenyl-beta-D-glucuronide

C12H15NO7 (285.0848)


   

(E)-2-[(3-Indole)cyanomethylene]-3-indolinone

(E)-2-[(3-Indole)cyanomethylene]-3-indolinone

C18H11N3O (285.0902)


   

4,9-anhydro-11-deoxyTTX

4,9-anhydro-11-deoxyTTX

C11H15N3O6 (285.0961)


   

7,8-Dehydrorutaecarpine

7,8-Dehydrorutaecarpine

C18H11N3O (285.0902)


   

2-Aminophenyl b-D-glucuronide HCl

2-Aminophenyl b-D-glucuronide HCl

C12H15NO7 (285.0848)


   

Nicotinic acid-hexoside

Nicotinic acid-hexoside

C12H15NO7 (285.0848)


   

N4-Acetylcytidine

N4-Acetylcytidine

C11H15N3O6 (285.0961)


CONFIDENCE standard compound; INTERNAL_ID 309

   

4-Acetylcytidine

4-Acetyl-1-(beta-delta-ribofuranosyl)cytosine

C11H15N3O6 (285.0961)


N4-Acetylcytidine is an endogenous metabolite. N4-Acetylcytidine is an endogenous metabolite.

   

coumarin 481

2H-1-Benzopyran-2-one, 7-(diethylamino)-4-(trifluoromethyl)-

C14H14F3NO2 (285.0977)


   

(2-Methyl-5-(morpholinosulfonyl)phenyl)boronic acid

(2-Methyl-5-(morpholinosulfonyl)phenyl)boronic acid

C11H16BNO5S (285.0842)


   

flunoxaprofen

flunoxaprofen

C16H12FNO3 (285.0801)


M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AE - Propionic acid derivatives G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CC - Antiinflammatory products for vaginal administration C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents

   

2-Fluoroadenosine

2-Fluoroadenosine

C10H12FN5O4 (285.0873)


2-Fluoroadenosine (2FA) is a nucleoside analogue. 2-Fluoroadenosine has antibacterial activity with IC50 value of 0.842 mM for Vibrio microvibrio[1].

   

2-Deoxy-2-fluoroguanosine

2-Deoxy-2-fluoroguanosine

C10H12FN5O4 (285.0873)


   

Methyl 3-(5-Methyl-2-(trifluoromethyl)-1H-indol-3-yl)propanoate

Methyl 3-(5-Methyl-2-(trifluoromethyl)-1H-indol-3-yl)propanoate

C14H14F3NO2 (285.0977)


   

(3S)-3-Benzyl-7a-(trifluoromethyl)tetrahydropyrrolo[2,1-b]oxa-zol-5(6H)-one

(3S)-3-Benzyl-7a-(trifluoromethyl)tetrahydropyrrolo[2,1-b]oxa-zol-5(6H)-one

C14H14F3NO2 (285.0977)


   

(3R)-3-Benzyl-7a-(trifluoromethyl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one

(3R)-3-Benzyl-7a-(trifluoromethyl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one

C14H14F3NO2 (285.0977)


   

1-(3-PYRROLIDINOPROYL)HOMOPIPERAZINE

1-(3-PYRROLIDINOPROYL)HOMOPIPERAZINE

C16H15NO2S (285.0823)


   

1-(ISOCYANO(TOSYL)METHYL)-2-METHYLBENZENE

1-(ISOCYANO(TOSYL)METHYL)-2-METHYLBENZENE

C16H15NO2S (285.0823)


   

5-(furan-2-yl)-3-p-tolyl-4,5-dihydro-1h-pyrazole-1-carbothioamide

5-(furan-2-yl)-3-p-tolyl-4,5-dihydro-1h-pyrazole-1-carbothioamide

C15H15N3OS (285.0936)


   

3-Deoxy-3-fluoroguanosine

3-Deoxy-3-fluoroguanosine

C10H12FN5O4 (285.0873)


   
   

4-Nitrophenylrhamnoside

4-Nitrophenyl α-L-rhamnopyranoside

C12H15NO7 (285.0848)


   

[5-chloro-2-(cyclopropylmethylamino)phenyl]-phenylmethanone

[5-chloro-2-(cyclopropylmethylamino)phenyl]-phenylmethanone

C17H16ClNO (285.092)


   

4-nitrophenyl-beta-l-fucopyranoside

p-Nitrophenyl 6-deoxy-beta-L-galactopyranoside

C12H15NO7 (285.0848)


   

4-AMINO-N-(2,3-DIMETHYLPHENYL)BENZAMIDE

4-AMINO-N-(2,3-DIMETHYLPHENYL)BENZAMIDE

C12H16ClN3O3 (285.088)


   

Methyl 7-fluoro-6-(phenylamino)-1H-benzo[d]imidazole-5-carboxylate

Methyl 7-fluoro-6-(phenylamino)-1H-benzo[d]imidazole-5-carboxylate

C15H12FN3O2 (285.0914)


   

Adenosine, 8-fluoro-

Adenosine, 8-fluoro-

C10H12FN5O4 (285.0873)


   

Asenapine

(3aS,12bS)-2-Methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole

C17H16ClNO (285.092)


N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AH - Diazepines, oxazepines, thiazepines and oxepines D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants An organic heterotetracyclic compound that is 2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrrole bearing methyl and chloro substituents at positions 2 and 5 respectively. C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Asenapine (Org 5222), an atypical antipsychotic, is an antagonist of serotonin receptors (pKi: 8.4-10.5), adrenoceptors (pKi: 8.9-9.5), dopamine receptors (pKi: 8.9-9.4) and histamine receptors (pKi: 8.2-9.0). Asenapine can be used in the research of schizophrenia and bipolar disorder[1][2].

   

1-propenyl-2,3-diMethyliMidazoliuM hexafluorophosphate

1-propenyl-2,3-diMethyliMidazoliuM hexafluorophosphate

C8H16F6N2P (285.0955)


   

DIETHYL(3-AMINOPROPYL)PHOSPHONATE OXALATE SALT

DIETHYL(3-AMINOPROPYL)PHOSPHONATE OXALATE SALT

C9H20NO7P (285.0977)


   

(4-(N-(3-Methylbutanoyl)sulfamoyl)phenyl)boronic acid

(4-(N-(3-Methylbutanoyl)sulfamoyl)phenyl)boronic acid

C11H16BNO5S (285.0842)


   

2-(1-PIPERAZINYL)-QUINOLINEHYDROCHLORIDE

2-(1-PIPERAZINYL)-QUINOLINEHYDROCHLORIDE

C13H17Cl2N3 (285.0799)


   

2-nitrophenyl β-D-fucoside

Orthonitrophenyl-beta-D-fucopyranoside

C12H15NO7 (285.0848)


   

1-(ISOCYANO(TOSYL)METHYL)-3-METHYLBENZENE

1-(ISOCYANO(TOSYL)METHYL)-3-METHYLBENZENE

C16H15NO2S (285.0823)


   

4-nitrophenyl-beta-d-fucopyranoside

4-nitrophenyl-beta-d-fucopyranoside

C12H15NO7 (285.0848)


   

7-benzoyl-2,4-dimethyl-2,4,7,8,9-pentazabicyclo[4.3.0]nona-8,10-diene-3,5-dione

7-benzoyl-2,4-dimethyl-2,4,7,8,9-pentazabicyclo[4.3.0]nona-8,10-diene-3,5-dione

C13H11N5O3 (285.0862)


   

8-(4-fluorophenyl)-2-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine

8-(4-fluorophenyl)-2-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine

C13H11F4N3 (285.0889)


   

4-(4-(HYDROXYMETHYL)-2-METHOXY-5-NITROPHENOXY)BUTANOIC ACID

4-(4-(HYDROXYMETHYL)-2-METHOXY-5-NITROPHENOXY)BUTANOIC ACID

C12H15NO7 (285.0848)


   

L-GAMMA-GLUTAMYL-P-NITROANILIDE MONOHYDRATE

L-GAMMA-GLUTAMYL-P-NITROANILIDE MONOHYDRATE

C11H15N3O6 (285.0961)


   

N-(4-Cyclopropyl-1-naphthalenyl)-2-formylhydrazinecarbothioamide

N-(4-Cyclopropyl-1-naphthalenyl)-2-formylhydrazinecarbothioamide

C15H15N3OS (285.0936)


   

2-{[(4-Methoxy-3-Methyl-2-Pyridinyl)Methyl]Sulfanyl}-1H-Benzimidazole

2-{[(4-Methoxy-3-Methyl-2-Pyridinyl)Methyl]Sulfanyl}-1H-Benzimidazole

C15H15N3OS (285.0936)


   

(4-Methoxy-3-(pyrrolidin-1-ylsulfonyl)phenyl)boronic acid

(4-Methoxy-3-(pyrrolidin-1-ylsulfonyl)phenyl)boronic acid

C11H16BNO5S (285.0842)


   

(2-Methyl-4-(morpholinosulfonyl)phenyl)boronic acid

(2-Methyl-4-(morpholinosulfonyl)phenyl)boronic acid

C11H16BNO5S (285.0842)


   

2′-Deoxy-2′-fluoroguanosine

2′-Deoxy-2′-fluoroguanosine

C10H12FN5O4 (285.0873)


2′-Deoxy-2′-fluoroguanosine, a nucleoside analog, is a potent inhibitor of influenza virus strains, with an EC90 of <0.35 μM for influenza virus A and B strains. 2′-Deoxy-2′-fluoroguanosine significantly inhibits replication of influenza virus in the upper respiratory tract, resulting in amelioration of fever and nasal inflammation[1][2].

   

2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-benzothiophene-5-carbonitrile

2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-benzothiophene-5-carbonitrile

C15H16BNO2S (285.0995)


   

2-AMINOPHENYL-β-D-GLUCURONIC ACID

2-AMINOPHENYL-β-D-GLUCURONIC ACID

C12H15NO7 (285.0848)


   

1-Isocyano-2-phenylethyl 4-methylphenyl sulfone

1-Isocyano-2-phenylethyl 4-methylphenyl sulfone

C16H15NO2S (285.0823)


   

N-(beta-D-glucosyl)nicotinate

N-(beta-D-glucosyl)nicotinate

C12H15NO7 (285.0848)


   

2-(6-Amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

2-(6-Amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

C10H12FN5O4 (285.0873)


D000970 - Antineoplastic Agents

   

5-BENZOXAZOLEACETIC ACID, 2-(4-FLUOROPHENYL)-alpha-METHYL-

5-BENZOXAZOLEACETIC ACID, 2-(4-FLUOROPHENYL)-alpha-METHYL-

C16H12FNO3 (285.0801)


   

N-(2-furanylmethyl)-3-methyl-7,8-dihydro-6H-cyclopenta[4,5]thieno[1,2-c]pyrimidin-1-amine

N-(2-furanylmethyl)-3-methyl-7,8-dihydro-6H-cyclopenta[4,5]thieno[1,2-c]pyrimidin-1-amine

C15H15N3OS (285.0936)


   

3-[2-(3-Methylphenoxy)ethyl]-1,3-benzothiazol-2-one

3-[2-(3-Methylphenoxy)ethyl]-1,3-benzothiazol-2-one

C16H15NO2S (285.0823)


   

3-[2-(4-Methylphenoxy)ethyl]-1,3-benzothiazol-2-one

3-[2-(4-Methylphenoxy)ethyl]-1,3-benzothiazol-2-one

C16H15NO2S (285.0823)


   

N-[1-[(2R,3S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]acetamide

N-[1-[(2R,3S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]acetamide

C11H15N3O6 (285.0961)


   

2-(6-amino-2-fluoro-7H-purin-8-yl)oxane-3,4,5-triol

2-(6-amino-2-fluoro-7H-purin-8-yl)oxane-3,4,5-triol

C10H12FN5O4 (285.0873)


   

4-butyl-3-(4-chloro-1,5-dimethyl-3-pyrazolyl)-1H-1,2,4-triazole-5-thione

4-butyl-3-(4-chloro-1,5-dimethyl-3-pyrazolyl)-1H-1,2,4-triazole-5-thione

C11H16ClN5S (285.0815)


   

N-(1-propyl-5-benzimidazolyl)-2-thiophenecarboxamide

N-(1-propyl-5-benzimidazolyl)-2-thiophenecarboxamide

C15H15N3OS (285.0936)


   

1-Butyl-3-[[(4,5-dimethyl-3-thiophenyl)-oxomethyl]amino]thiourea

1-Butyl-3-[[(4,5-dimethyl-3-thiophenyl)-oxomethyl]amino]thiourea

C12H19N3OS2 (285.0969)


   

N-[3-(6-imidazo[2,1-b]thiazolyl)phenyl]butanamide

N-[3-(6-imidazo[2,1-b]thiazolyl)phenyl]butanamide

C15H15N3OS (285.0936)


   

(2R,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol

(2R,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol

C10H12FN5O4 (285.0873)


   

5-[2-(2,6-Difluorophenyl)ethyl]-8-quinolinol

5-[2-(2,6-Difluorophenyl)ethyl]-8-quinolinol

C17H13F2NO (285.0965)


   

N-(D-glucopyranosyl)nicotinate

N-(D-glucopyranosyl)nicotinate

C12H15NO7 (285.0848)


   

3-Methyl-4-thiophen-2-yl-2,4,4a,6,7,8-hexahydropyrazolo[3,4-b]quinolin-5-one

3-Methyl-4-thiophen-2-yl-2,4,4a,6,7,8-hexahydropyrazolo[3,4-b]quinolin-5-one

C15H15N3OS (285.0936)


   

(1R,10S,11R,12R,13S,14R)-3-amino-11-(hydroxymethyl)-6,9-dioxa-2,4-diazapentacyclo[8.3.1.01,7.05,13.08,12]tetradec-3-ene-8,11,14-triol

(1R,10S,11R,12R,13S,14R)-3-amino-11-(hydroxymethyl)-6,9-dioxa-2,4-diazapentacyclo[8.3.1.01,7.05,13.08,12]tetradec-3-ene-8,11,14-triol

C11H15N3O6 (285.0961)


   

[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] butanoate

[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] butanoate

C9H20NO7P (285.0977)


   

(S,S)-asenapine

(S,S)-asenapine

C17H16ClNO (285.092)


A 5-chloro-2-methyl-2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrrole in which both of the stereocentres have S configuration.

   

(R,R)-asenapine

(R,R)-asenapine

C17H16ClNO (285.092)


A 5-chloro-2-methyl-2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrrole in which both of the stereocentres have R configuration.

   

4-nitrophenyl alpha-L-fucoside

4-nitrophenyl alpha-L-fucoside

C12H15NO7 (285.0848)


An alpha-L-fucoside that is alpha-L-fucopyranose in which the anomeric hydroxy hydrogen is replaced by a 4-nitrophenyl group.

   
   

PI3K/Akt/mTOR-IN-2

PI3K/Akt/mTOR-IN-2

C17H13F2NO (285.0965)


PI3K/Akt/mTOR-IN-2 is a PI3K/AKT/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC50 value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis[1].

   

7-imino-2-methyl-10,13,15-trioxa-6,8-diazapentacyclo[7.4.1.1³,¹².0⁵,¹¹.0⁵,¹⁴]pentadecane-2,4,12-triol

7-imino-2-methyl-10,13,15-trioxa-6,8-diazapentacyclo[7.4.1.1³,¹².0⁵,¹¹.0⁵,¹⁴]pentadecane-2,4,12-triol

C11H15N3O6 (285.0961)


   

(1r,2s,3s,4s,5r,9s,11s,12s,14r)-7-imino-2-methyl-10,13,15-trioxa-6,8-diazapentacyclo[7.4.1.1³,¹².0⁵,¹¹.0⁵,¹⁴]pentadecane-2,4,12-triol

(1r,2s,3s,4s,5r,9s,11s,12s,14r)-7-imino-2-methyl-10,13,15-trioxa-6,8-diazapentacyclo[7.4.1.1³,¹².0⁵,¹¹.0⁵,¹⁴]pentadecane-2,4,12-triol

C11H15N3O6 (285.0961)


   

3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(10),4(9),5,7,11,15,17,19-nonaen-14-one

3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(10),4(9),5,7,11,15,17,19-nonaen-14-one

C18H11N3O (285.0902)


   

(2s)-2-amino-4-(3,4-dihydroxy-5-methoxybenzoyloxy)butanoic acid

(2s)-2-amino-4-(3,4-dihydroxy-5-methoxybenzoyloxy)butanoic acid

C12H15NO7 (285.0848)


   

3,11,21-triazapentacyclo[11.8.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2,4,6,8,13,15,17,19-nonaen-10-one

3,11,21-triazapentacyclo[11.8.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2,4,6,8,13,15,17,19-nonaen-10-one

C18H11N3O (285.0902)


   

(3s)-3-hydroxy-3-[(2-hydroxy-4,5-dimethoxyphenyl)-c-hydroxycarbonimidoyl]propanoic acid

(3s)-3-hydroxy-3-[(2-hydroxy-4,5-dimethoxyphenyl)-c-hydroxycarbonimidoyl]propanoic acid

C12H15NO7 (285.0848)


   

3-hydroxy-3-[(2-hydroxy-4,5-dimethoxyphenyl)-c-hydroxycarbonimidoyl]propanoic acid

3-hydroxy-3-[(2-hydroxy-4,5-dimethoxyphenyl)-c-hydroxycarbonimidoyl]propanoic acid

C12H15NO7 (285.0848)


   

2-amino-4-(3,4-dihydroxy-5-methoxybenzoyloxy)butanoic acid

2-amino-4-(3,4-dihydroxy-5-methoxybenzoyloxy)butanoic acid

C12H15NO7 (285.0848)